Limited Competition for NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (UH3)

The summary for the Limited Competition for NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (UH3) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Limited Competition for NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (UH3): The National Center for Advancing Translational Sciences (NCATS) seeks to expand the therapeutics discovery program piloted in 2012, to explore new therapeutic uses for proprietary drug candidates (Agents) across a broad range of human diseases. This innovative program allows investigators to propose new therapeutic uses for Agents from pharmaceutical company partners. A strong application will be supported by scientific evidence that modulation of the Agents target will have a positive impact on the disease/condition. PAR-14-213 encourages X02 pre-applications for the NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules.The X02 pre-application is the first step in the application process for PAR-14-212, PAR-14-210, and PAR-14-211; applicants must read all of the companion FOAs.The X02 pre-applications will be evaluated by outside experts. Investigators whose X02 pre-applications are judged to be the most meritorious will be notified of the opportunity to submit a UH3 application under this FOA or a UH2/UH3 under PAR-14-212 or a UH2/UH3 application under PAR-14-210 in the case of a pediatric indication. The UH3 will support milestone-driven Phase 2a trials to demonstrate that the Agent, made available for this program by the pharmaceutical partners, modulates the target and has the potential to yield the desired clinical outcome in the proposed disease population.
Federal Grant Title: Limited Competition for NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (UH3)
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health Income Security and Social Services
Type of Opportunity: Discretionary
Funding Opportunity Number: PAR-14-211
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.103, 93.121, 93.173, 93.242, 93.273, 93.279, 93.350, 93.853, 93.865, 93.866, 93.867
CFDA Descriptions: Food and Drug Administration_Research; Oral Diseases and Disorders Research; Research Related to Deafness and Communication Disorders; Mental Health Research Grants; Alcohol Research Programs; Drug Abuse and Addiction Research Programs; National Center for Advancing Translational Sciences; Extramural Research Programs in the Neurosciences and Neurological Disorders; Child Health and Human Development Extramural Research; Aging Research; Vision Research
Current Application Deadline: Jan 16, 2015
Original Application Deadline: Jan 16, 2015
Posted Date: May 12, 2014
Creation Date: May 12, 2014
Archive Date: Feb 16, 2015
Total Program Funding:
Maximum Federal Grant Award: none
Minimum Federal Grant Award: none
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
For profit organizations other than small businesses
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Native American tribal governments (Federally recognized)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
State governments
Special district governments
Small businesses
Private institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
County governments
Public and State controlled institutions of higher education
Independent school districts
City or township governments
Additional Information on Eligibility
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/pa-files/PAR-14-211.html
Grant Announcement Contact
NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants
Development and Maintenance of the Animal Food Regulatory Program Standards (U19) Clinical...
Use of Digital Health Technologies in Clinical Investigations to Support Drug and Biologic...
Cooperative Agreement to Support the World Trade Organization's (WTO) Standards and Trade ...
Cooperative Agreement for Long Term Data Collection on Antimicrobial Use in Animals (U01) ...
Alliance to Support the Activities of the Integrated Food Safety System (IFSS), including ...
Support for Small Scientific Conference Grant Program
Cooperative Agreement to Support the World Health Organization (WHO) International Program...
Clinical Studies of Safety and Effectiveness of Orphan Products
More Grants from the National Institutes of Health
Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical ...
Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Mino...
Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowe...
NINDS Program Project Grant (P01 Clinical Trial Optional)
Centers for Research in Emerging Infectious Diseases (CREID) Network (U01 Clinical Trial N...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com